TNF-a expression is elevated in a variety of neuropathologies, including multiple sclerosis, cerebral malaria and HIV encephalitis. However, the consequences of such high cerebral TNF-a expression remain unresolved. Here, using MRI, we demonstrate that a focal intrastriatal injection of TNF-a causes a signi®cant, acute reduction (15±30%) in cerebral blood volume (CBV), which is dependent on TNF-a-type 2 receptor (TNFR2) activation, and can be ameliorated by pretreatment with a non-speci®c endothelin (ET) receptor antagonist. An acute breakdown of the blood-cerebrospinal¯uid barrier (B-CSF-B) and a delayed breakdown of the blood-brain barrier (BBB) were also observed using contrast-enhanced MRI. Furthermore, a signi®cant reduction in tissue water diffusion was apparent 24 h after intrastriatal injection of TNF-a injection, which may indicate compromise of tissue energy metabolism. Prolonged expression of endogenous TNF-a, achieved through the use of an adenoviral vector expressing TNF-a cDNA (Ad5TNF-a m ), caused a sustained depression in CBV in accordance with the single TNF-a bolus data. These ®ndings identify vasoconstriction, disrupted tissue homeostasis and damage to the BBBs as adverse effects of TNF-a within the brain, and suggest that antagonists of the endothelin and TNF-a type 2 receptors may be therapeutic in TNF-a-associated neuropathologies.
Introduction
Expression of the proin¯ammatory cytokine tumour necrosis factor alpha (TNF-a) is associated with the pathology of a broad spectrum of CNS disease and injury. However, the consequences of TNF-a expression, whether detrimental or protective, remain a focus for debate.
TNF-a has been quanti®ed in post-mortem tissue from the brains of patients with both acute and chronic neuropathologies, such as cerebral malaria (Brown et al., 1999) and HIV-1 (Achim et al., 1993; Nuovo et al., 1994) , indicating local production of the cytokine. TNF-a expression has also been detected in post-mortem brain tissue from patients with bacterial meningitis (Waage et al., 1989; Brown et al., 1999) , a condition in which intrathecal levels of TNF-a correlate positively with the degree of blood-brain barrier (BBB) breakdown, disease severity and indices of meningeal in¯ammation (Sharief et al., 1992) . Furthermore, TNF-a expression is associated with demyelinating multiple sclerosis lesions (Woodroofe and Cuzner, 1993) , and the presence of TNF-a in cerebrospinal¯uid from multiple sclerosis patients correlates with disease activity (Hauser et al., 1990 ).
Thus, the accumulated evidence suggests a role for TNF-a in the pathophysiology of a variety of CNS diseases, although the mechanisms by which this cytokine contributes to disease or injury severity remain unresolved.
Following both stroke and trauma, the in¯ammatory response has been shown to contribute to secondary injury and increased lesion volume (Clark et al., 1994; Matsuo et al., 1994) . However, although TNF-a is the archetypal proin¯ammatory cytokine, it can be both neurotoxic and neuroprotective in models of cerebral ischaemia and head injury (Bruce et al., 1996; Dawson et al., 1996; Shohami et al., 1996 Shohami et al., , 1999 Barone et al., 1997; Nawashiro et al., 1997; Lavine et al., 1998; Scherbel et al., 1999) . It has been suggested that in the early stages of injury, over-expression of TNF-a is deleterious, while at later time points it may aid recovery of injured tissue (Scherbel et al., 1999; Shohami et al., 1999) . Recently, Arnett and colleagues reported that TNF-a activity contributes to remyelination in the cuprizone model (Arnett et al., 2001) . In addition, Gourin and Shackford (1997) reported elevated TNF-a levels in cerebral microvascular endothelium isolated from head-injured patients, suggesting possible cerebrovascular effects of this cytokine.
MRI is used clinically for the evaluation of many neuropathologies in which in¯ammation is implicated. Conventional MRI provides a sensitive measure of tissue structure and water content and, together with intravenous contrast agents, can measure BBB permeability and cerebral perfusion. In addition, diffusion-weighted imaging has demonstrated sensitivity to reversible and irreversible alterations in cellular homeostasis that are undetectable histologically, notably in acute ischaemia and spreading depression (HoehnBerlage, 1995) . Owing to the non-invasive nature of MRI, these techniques are ideally suited to the temporal evaluation of brain disease, and are particularly of value in understanding the contribution of cytokines to CNS injury and disease in vivo (Blamire et al., 2000) .
In this study, MRI techniques were used to investigate the effects of a focal striatal injection of recombinant rat TNF-a (rrTNF-a) on cerebral blood volume (CBV), on BBB and blood-cerebrospinal¯uid barrier (B-CSF-B) viability, and on tissue water diffusion in the rat brain. The mechanism and pathway underlying the observed changes in CBV were investigated in two further experiments: (i) pre-treatment with an endothelin (ET) receptor antagonist prior to intrastriatal rrTNF-a; and (ii) intrastriatal injection of recombinant human TNF-a (rhuTNF-a), which only binds to the TNF-a type 1 receptor (TNFR1) in rat brain. In addition, the effects of prolonged endogenous TNF-a expression on CBV were determined by intrastriatal injection of a replication-de®cient recombinant adenovirus expressing membrane-bound TNF-a cDNA (Ad5TNF-a m ), which causes local, sustained expression of TNF-a (Marr et al., 1997) . The results of these studies demonstrate diverse actions of TNF-a in the brain and provide a mechanistic basis by which this cytokine may contribute to the pathogenesis of diseases associated with TNF-a expression within the brain parenchyma.
Materials and methods

Animal preparation
Adult male Wistar rats (Harlan-Olac, UK), weighing 218 T 20 g, were anaesthetized with fentanyl/¯uanisone and midazolam (0.68 ml/kg of each). Using a <50 mm-tipped glass pipette, 1 ml of TNF-a (NIBSC, Potters Bar, UK) solution was injected stereotaxically over a 10-min period, 1 mm anterior and 3 mm lateral to bregma, at a depth of 4 mm into the left striatum. Animals were injected with 0.3 mg/ml or 1.5 mg/ml of either recombinant rat TNF-a (rrTNF-a) or recombinant human TNF-a (rhuTNF-a), each in 0.1% BSA (bovine serum albumin) in low-endotoxin saline, or with vehicle solution only. In addition, two further groups of animals were injected stereotaxically in the same way with 10 7 p.f.u. of a replication-de®cient recombinant adenoviral vector (Kolb et al., 2001 ) in 1 ml of saline: (i) adenovirus expressing murine membrane-bound TNF-a cDNA (Ad5TNF-a m ); and (ii) a control adenovirus with no insert in the E1 region (AdDL70). Animals were positioned in the MRI probe (3.4 cm internal diameter Alderman-Grant resonator) using a bite-bar. During MRI, anaesthesia was maintained with 0.8±1.2% halothane in 50% N 2 O/50% O 2 , ECG was monitored non-invasively and body temperature was maintained at~37°C. All procedures were approved by the United Kingdom Home Of®ce.
MRI studies
Magnetic resonance images were acquired using a 300 MHz Varian Inova spectrometer (Varian, Palo Alto, CA). Anatomical images were acquired using a T 2 -weighted sequence [repetition time (TR) 3 s, echo time (TE) 80 ms]. Diffusion-weighted images were acquired using a pulsedgradient spin-echo sequence (TR 1.0 s, TE 40 ms), with diffusion weighting values of 125, 750 and 1500 s/mm 2 , a diffusion time of 20 ms and a diffusion gradient duration of 10 ms. Diffusion gradients were applied separately along three orthogonal axes and apparent diffusion coef®cient (ADC)`trace' maps were calculated (Basser et al., 1994) . Navigator echoes were used for motion correction (Ordidge et al., 1994) . Regional CBV (rCBV) maps were generated from time-series images acquired during bolus injection of contrast agent and tracer kinetic analysis (Rosen et al., 1990) . A series of 40 FLASH images (Frahm et al., 1986) were acquired at a rate of 1 image per second, while 100 ml of a gadolinium-based contrast agent (Gd) (Omniscan, Nycomed Amersham, UK) was injected via a tail vein, over a 4 s period, from image 8. Spin-echo T 1 -weighted images (TR 500 ms, TE 20 ms) were acquired both pre-Gd injection and 10 min post-Gd injection to look for image enhancement owing to BBB/B-CSF-B permeability. Slice thickness was 1 mm for coronal images and 2 mm for horizontal images, except for the rCBV data sets, which were all 1 mm. The matrix size and ®eld of view were 128 Q 128 and 3 Q 3 cm, respectively, for all images, except for the rCBV data, which were acquired with a 128 Q 64 matrix and a 3 Q 2 cm ®eld of view. All regions of interest (ROI) and statistical analyses were performed on images obtained in the horizontal plane (at the level of the injection site) at the time-points stated, although coronal plane data was also acquired at intermediate times for qualitative purposes.
Experimental protocol
Six studies were performed to investigate different aspects of the brain response to TNF-a.
Acute effects of a TNF-a single bolus injection on rCBV and B-CSF-B/BBB viability Three groups of animals were used and injected with: (i) vehicle only (n = 4); (ii) 0.3 mg rrTNF-a (n = 6); or (iii) 1.5 mg rrTNF-a (n = 5). Pre-Gd T 1 -weighted images, rCBV data and post-Gd T 1 -weighted images were acquired at 1.5, 2.5, 3.5 and 5.5 h. One animal from each of the rrTNF-a-injected groups was sacri®ced at 5.5 h for histological and immunocytochemical analysis. All other animals were recovered from anaesthesia at the end of the MRI protocol, except for two which died for reasons unrelated to the rrTNF-a (0.3 mg) injection.
Acute effects of a TNF-a single bolus injection on tissue water diffusion Two groups of animals were used and were injected with: (i) vehicle only (n = 4); or (ii) 0.3 mg rrTNF-a (n = 7). Diffusionand T 2 -weighted images were acquired each hour (1.5±6.5 h) after TNF-a injection. All animals were recovered from anaesthesia at the end of the MRI protocol, except for two, which died for reasons unrelated to the rrTNF-a injection.
Chronic effects of a TNF-a single bolus injection
In studies (a) and (b), animals that were recovered from anaesthesia after the ®nal acquisition were re-imaged using all MRI protocols at either 24 h (control, n = 4; 0.3 mg rrTNF-a, n = 8; 1.5 mg rrTNF-a, n = 4) or 72 h (control, n = 3; 0.3 mg rrTNF-a, n = 6) after stereotaxic injection.
The groups injected with 0.3 mg rrTNF-a include additional animals that were imaged at either 24 h or 72 h only, to replace animals that died or were used for histology at earlier time points.
Effect of an ET receptor antagonist on acute CBV changes
Two groups of animals were used, and were treated as follows: (i) intravenous injection of the non-speci®c ET receptor antagonist Ro 46-2005 (1 mg in 0.25 ml sterile water) 10 min before injection of 1.5 mg rrTNF-a (n = 6); and (ii) intravenous injection of sterile water (0.25 ml) 10 min before injection of 1.5 mg rrTNF-a (n = 4). Pre-Gd T 1 -weighted images, rCBV data and post-Gd T 1 -weighted images were acquired at 1.5 h only. An additional group of animals treated as for group (i) were imaged using all MRI protocols at 24 h (n = 4). The dose of Ro 46-2005 used in this study has been found to be an effective therapy in other models of acute CNS injury and disease (Clozel et al., 1993) .
Effects of TNF-a type I receptor activation alone on acute CBV changes Two groups of animals were used, and were injected with: (i) 0.3 mg rhuTNF-a (n = 5); or (ii) 1.5 mg rhuTNF-a (n = 5). PreGd T 1 -weighted images, rCBV data and post-Gd T 1 -weighted images were acquired at 1.5 h only. All animals were recovered from anaesthesia and subsequently re-imaged at 24 h with all MRI protocols.
Effects of prolonged endogenous TNF-a expression on CBV Animals were studied using MRI at either 24 h or 48 h after adenovirus injection: (i) Ad5TNF-a m (24 h, n = 4; 72 h, n = 3); or (ii) AdDL70 (n = 3 per time point). Pre-Gd T 1 -weighted images, rCBV data and post-Gd T 1 -weighted images were acquired for each animal.
Following end-point MRI, the brains of all animals were perfusion-®xed for histological and immunocytochemical analysis. To quantitate leukocyte recruitment and horseradish peroxidase (HRP)-detectable changes in BBB/B-CSF-B permeability, additional animals were (i) injected with 0.3 mg rrTNF-a and perfusion-®xed at 4 h (n = 3), or (ii) injected with 1.5 mg rrTNF-a and perfusion-®xed at either 2.5 h (n = 2) or 5.5 h (n = 2). Additional animals were injected with adenovirus (Ad5TNF-a m , n = 6; or AdDL70, n = 6), and perfusion-®xed at either 5 or 14 days to look for neuronal loss.
Histological analysis
At the end of each protocol, the rats were deeply anaesthetized with sodium pentobarbitone, and transcardially perfused with 200 ml 0.9% heparinized saline followed by 200 ml periodate lysine paraformaldehyde. After dissection, the brains were post-®xed for several hours in the ®xative and then immersed in 30% sucrose buffer for 24 h to cryoprotect them. The tissue was then embedded in Tissue Tek (Miles Inc, Elkhart, IN, USA) and frozen in isopentane at ±40°C. Cresyl violet-stained sections (50 mm) were examined for signs of neuronal damage and for the presence of leukocytes. Immunohistochemistry was used to con®rm the presence and distribution of speci®c cell populations. Frozen, 10-mm thick serial sections were cut from the ®xed tissue and mounted on gelatin-coated glass slides. Antigens were detected using a three-step indirect method (Hsu et al., 1981) . Polymorphonuclear neutrophils were identi®ed using the antineutrophil serum HB199 (Anthony et al., 1998) and macrophages were identi®ed using the monoclonal antibody ED1 (Dijkstra et al., 1985) , which stains most macrophage populations including recruited monocytes, but not quiescent microglia. In each group of animals, leukocyte in®ltration was quanti®ed by counting the number of ED1-positive or HB199-positive cells in 10-mm thick cresyl violet counterstained sections from regions immediately adjacent to the injection site. Three non-overlapping ®elds containing the highest density of recruited cells within the parenchyma were chosen and the number of neutrophils or macrophages was calculated as an average number per mm 2 for each animal. Neurones were identi®ed using anti-NeuN monoclonal antibody (Chemicon, Europe, Ltd, Chandlers Ford, Hampshire, UK) and 25-mm thick frozen sections were processed for cholinesterase histochemistry using acetylthiocholine as substrate.
Some animals were injected intravenously with type-II HRP, an indicator of increased BBB permeability (Sigma Chemical Co., St Louis, MO, USA), 10 4 U/kg, 30 min before perfusion±®xation. Coronal, free-¯oating sections were cut for HRP localization by a modi®ed Hanker±Yates method (Perry and Linden, 1982) . HRP has been used extensively as a tracer of altered vessel permeability, and does not increase endothelial transport under normal conditions (Claudio et al., 1990) .
MRI data analysis
ROIs encompassing the striatum were de®ned on T 2 -weighted images in each hemisphere (see Fig. 1C ), and applied to all images or calculated data maps for quantitation. During the acute time courses, animals remained in the magnet throughout, enabling the same ROI to be used for all images acquired over this period. At the later time points, both the imaging slice position and the ROIs were matched to those used at earlier time points. For the rCBV maps and T 2 -weighted images, the data are expressed as a ratio of injected/ non-injected striatal values. The signal intensity was calculated for the injected striatum in the pre-Gd and post-Gd images, and the percentage increase in signal in the post-Gd images calculated (normalized for the changes in signal intensity of the contralateral striatum between pre-and postGd images). All values are mean T standard deviation (SD).
Since data were not acquired at every time point from all animals over the acute time course (for technical reasons), a mixed-effect model followed by pair-wise t-tests (Vonesh and Chinchilli, 1997) was used to determine any statistical differences between the rCBV time courses for each group. Unpaired or paired t-tests were used to determine signi®cant differences at 24 and 72 h for all MRI parameters.
Results
The minimally invasive technique used to focally microinject TNF-a into the brain parenchyma resulted in no visible damage per se, as demonstrated by vehicle-injected animals in which no leukocyte recruitment or damage to the brain parenchyma was found at either 24 h or 72 h after injection. Previous studies have demonstrated that there is no leukocyte recruitment at earlier times in vehicle-injected animals Fig. 1 rCBV maps acquired after a focal striatal injection of TNF-a. (A) rCBV map calculated from perfusion time-series MRI data acquired 1.5 h after injection of rrTNF-a (1.5 mg). The ROIs used for quantitative data analysis are indicated for each striatum. An area of reduced CBV can be seen in the injected (left) striatum. (B) rCBV map calculated from perfusion time-series MRI data acquired 5.5 h after injection of rrTNF-a (1.5 mg), demonstrating that CBV in the injected (left) striatum has mostly returned to normal by this time point. (C) T 2 -weighted image acquired 1.5 h after injection of rrTNF-a (1.5 mg). The small area of increased signal intensity in the left striatum indicates the site of intrastriatal injection. The ROIs used for quantitative data analysis are indicated for each striatum. All non-CNS tissue has been excluded from the rCBV maps. (Anthony et al., 1997) . On T 2 -weighted scout images at 1 h, the injection bolus was visible as a small hyperintense area in the left striatum in all animals (Fig. 1C) , and subsequent scans were positioned directly through the injection site. Owing to the focal nature of the cytokine injection into the left striatum, inter-hemisphere comparisons were possible between injected and non-injected striatal values.
Acute effects of a TNF-a single bolus injection on CBV
An acute reduction in rCBV was observed in the injected striatum at 1.5 h after rrTNF-a injection into the brain (Fig. 1A) , which gradually returned to normal by~5.5 h (Fig. 1B) . No differences in rCBV between the two hemispheres were visible in vehicle-injected animals at any time point. Local changes in CBV were assessed by calculating the ratio of rCBV within an ROI in the injected striatum to that in a matched area in the non-injected striatum of the same animal (Fig. 1) . In animals injected with either 0.3 or 1.5 mg of rrTNF-a, the ratio of injected/non-injected striatal rCBV was signi®cantly reduced compared with the vehicle-injected group at 1.5 h (unpaired t-tests: P < 0.02, 0.3 mg rrTNF-a; P < 0.0002, 1.5 mg rrTNF-a) (Fig. 2) . This reduction in rCBV was dose-dependent, with a greater reduction at the higher dose (~25%) than at the lower dose (~14%). The rCBV changes occurred prior to leukocyte recruitment to the brain parenchyma, which was ®rst evident 4 h after the injection of rrTNF-a. At 4±5.5 h after rrTNF-a injection, a small number of recruited monocytes (ED1-stained cells) were visible in cuffs around the vessels penetrating the cortex (50.8 T 5.0 mm ±2 with 0.3 mg rrTNF-a, n = 3; 59.2 T 19.4 mm ±2 with 1.5 mg rrTNF-a, n = 3).
The reduction in rCBV at 1.5 h in the injected striatum was eliminated by intravenous injection of the ET receptor antagonist Ro 46-2005 (5 mg/kg) 10 min prior to intracerebral rrTNF-a injection (Fig. 3) . In control animals injected intravenously with the vehicle 10 min prior to intracerebral rrTNF-a (1.5 mg), the reduction in striatal rCBV was still evident, and comparable to that in the initial group of animals injected with 1.5 mg rrTNF-a (Fig. 3) . The difference between injected/non-injected striatal rCBV ratios for the two groups receiving an intravenous injection (either Ro 46-2005 or vehicle) prior to intracerebral rrTNF-a injection was highly signi®cant (unpaired t-test, P < 0.005).
Animals injected with either 0.3 or 1.5 mg rhuTNF-a exhibited no reduction in rCBV at 1.5 h (Fig. 3) . There was no signi®cant difference in the injected/non-injected striatal rCBV ratios between either of these two groups and the vehicle-injected group, indicating that activation of the rat TNFR1 alone by rhuTNF-a does not result in a reduction in rCBV.
Acute effects of a TNF-a single bolus injection on B-CSF-B and BBB integrity
From as early as 1.5 h after injection of 1.5 mg rrTNF-a (2± 3 h with 0.3 mg rrTNF-a), enhancement of the ipsilateral meninges was evident on T 1 -weighted images acquired 10 Asterisks indicate a signi®cant difference between control and treated groups: *P < 0.05, **P < 0.02, ***P < 0.005, ****P < 0.002, *****P < 0.001. min after intravenous administration of a contrast agent. When the BBB and B-CSF-B are intact, the intravascular contrast agent cannot cross these barriers, and, consequently, no signal changes are seen on post-contrast T 1 -weighted images. Thus, enhancement in post-contrast T 1 -weighted images, as observed here, indicates breakdown of the B-CSF-B, and was ®rst seen in the meninges overlying the parietal cortex. The breakdown of the B-CSF-B was not detected by histochemical localization of the tracer HRP at this time point, and preceded recruitment of any leukocytes to the meninges. Pre-treatment with Ro 46-2005 did not signi®-cantly alter the effect of rrTNF-a on the B-CSF-B at 1.5 h. Intrastriatal injection of rhuTNF-a yielded a similar degree of meningeal enhancement at 1.5 h to that seen with rrTNF-a.
Over subsequent hours, the B-CSF-B breakdown spread to encompass meningeal layers surrounding the frontal cortex ( Fig. 4B and C) . Marked mononuclear cell recruitment to the meninges occurred from~4 h, and by 5.5 h the B-CSF-B breakdown was just visible histologically using HRP (Fig. 4D) . In some cases, the MRI signal enhancement appeared to have spread into the outermost cortical layers by 5.5 h, suggesting compromise of the pial and cortexpenetrating vessels. In the coronal plane, we observed meningeal enhancement around the entire injected hemisphere (Fig. 4C) , and this was often particularly clear around the piriform cortex where upon histological examination we found large numbers of monocytes (1390 T 444 mm ±2 with 1.5 mg rrTNF-a, n = 3) (Fig. 4E) . No breakdown of the B-CSF-B was observed in vehicle-injected animals at any time point.
Acute effects of a TNF-a single bolus injection on tissue water diffusion From 1 to 4 h, we observed small increases in tissue water diffusion at the injection site, which corresponded spatially to regions of T 2 hyperintensity, in all animals imaged for T 2 and diffusion over the acute time course. This acute increase in both T 2 signal intensity (5±13%) and diffusion (6±8%) re¯ects the small increase in extracellular water arising from the injection bolus, and resolved as the¯uid was cleared.
Chronic effects of a TNF-a single bolus injection on tissue water diffusion, B-CSF-B/ BBB integrity and CBV Although ELISA (enzyme-linked immunosorbent assay) measurements show that all TNF-a has been cleared from the brain parenchyma by 24 h after a bolus injection (Anthony et al., 2001) , the ADC of tissue water in the injected striatum (ROI delineated as for rCBV) was signi®cantly reduced compared with the non-injected striatum in both of the rrTNF-a-injected groups (0.3 and 1.5 mg) at 24 h (paired t-tests, P < 0.02) ( Table 1) . Despite the focal nature of the cytokine injection, the reduction in ADC was not restricted to the striatum and also encompassed surrounding cortical regions (Fig. 5A) . The ADC reduction observed in the rrTNFa-injected animals did not appear to be dose-dependent, with similar reductions (7±13%) in both groups. There were no signi®cant differences between the injected and non-injected hemispheres in the control animals. The reduction in ADC was not affected by pre-treatment with the ET-receptor antagonist Ro 46-2005, with a signi®cant difference (paired ttest, P < 0.03) between the injected and non-injected striatal values being evident (Table 1) . Similarly, there was a signi®cant difference between the injected and non-injected striatal ADC values in the animals injected with 1.5 mg rhuTNF-a (paired t-test, P < 0.02) (Table 1) . However, although a reduction in ADC was apparent in the injected hemisphere in three out of ®ve animals injected with the lower dose (0.3 mg) of rhuTNF-a, this did not reach signi®cance (paired t-test, P = 0.136).
Breakdown of the B-CSF-B in all animals injected with rrTNF-a and rhuTNF-a persisted to 24 h, when large numbers of monocytes were present in the meninges. Lowlevel breakdown of the BBB in the brain parenchyma was also observed 24 h after rrTNF-a injection on post-contrast T 1 -weighted images. This breakdown was more evident with the higher dose (1.5 mg) of rrTNF-a (increase in signal intensity of injected striatum post-Gd versus pre-Gd of 8.1 T 2.1%), but less apparent than that observed previously following intrastriatal IL-1b injection (Blamire et al., 2000) . The pattern of BBB breakdown was similar to the tissue water diffusion changes at 24 h, encompassing both striatal and cortical regions (Fig. 5B) . At this time point, recruitment of monocytes into the brain parenchyma was marked (189 T 7 per mm 2 with 0.3 mg rrTNF-a, n = 3). Pretreatment with the ET-receptor antagonist Ro 46-2005 did not signi®cantly affect the level of BBB breakdown observed in animals injected with 1.5 mg TNF-a (increase in signal intensity of injected striatum of 10.3 T 2.7%). However, in animals injected with 1.5 mg rhuTNF-a, the degree of BBB breakdown appeared to be substantially reduced (increase in signal intensity of injected striatum = 5.2 T 1.6%), which may be related to a lower level of monocyte recruitment (95 T 33 mm ±2 , n = 3) compared with that induced by rrTNF-a at this time point.
Despite both diffusion and BBB changes in the TNF-ainjected groups, there were no signi®cant differences in either rCBV or T 2 signal intensity between the injected and noninjected hemispheres at 24 h in any animals.
Seventy-two hours after rrTNF-a injection, both the BBB and B-CSF-B were intact, and no signi®cant differences were found in the ADC of tissue water, T 2 intensity or rCBV between the hemispheres in any animals. However, the number of ED-1-positive macrophages present within the brain parenchyma was elevated further (361 T 79 mm ±2 with 0.3 mg rrTNF-a, n = 3) at this time. There was no apparent neuronal cell death at any time point following the single Values are represented as mean T SD for n = 4 (control groups), n = 8 (0.3 mg rrTNF-a, 24 h), n = 6 (0.3 mg rrTNF-a, 72 h), n = 4 (1.5 mg rrTNF-a, 24 h), n = 4 (Ro 46-2005 + 1.5 mg rrTNF-a, 24 h), n = 5 (0.3 mg rhuTNF-a, 24 h) and n = 5 (1.5 mg rhuTNF-a, 24 h). Signi®cant differences from control (right) striatum were determined by paired t-tests:
bolus injections of rrTNF-a or rhuTNF-a, as evidenced by cresyl violet staining.
Effects of prolonged endogenous TNF-a expression on CBV
A progressive decrease in rCBV was observed in the injected striatum of animals injected with Ad5TNF-a m . The reduction in rCBV reached~20% by 48 h (Fig. 6 ). This decrease in rCBV was highly signi®cant compared with animals injected with a control adenovirus (AdDL70) at both 24 and 48 h (unpaired t-tests, P < 0.005). At both 5 and 14 days after the injection of Ad5TNF-a m , unlike the single bolus injection, there was evidence of neuronal cell death in the lesion as indicated by a loss of NeuN antigen expression and a reduction in acetylcholinesterase activity (Fig. 7) . There was no reduction in NeuN staining or loss of acetylcholinesterase activity following injection of AdDL70.
Discussion
In this study we have shown that a focal, intrastriatal injection of TNF-a in the rat brain results in: (i) an acute, dosedependent reduction in CBV that is mediated by endothelin, and coupled to activation of the TNF-a type 2 receptor (TNFR2) pathway; (ii) early breakdown of the blood-CSF barrier and delayed breakdown of the blood-brain barrier; and (iii) a delayed reduction in tissue water diffusion. At all times leukocyte recruitment to the brain (parenchyma and meninges) was restricted solely to mononuclear cells, as reported previously (Anthony et al., 1997; Glabinski et al., 1998) . In addition, experiments using a replication-de®cient recombinant adenovirus expressing membrane-bound TNF-a cDNA con®rmed that prolonged expression of endogenous TNF-a causes a sustained decrease in rCBV. These results are in contrast to our previous ®ndings following intrastriatal injection of IL-1b, which induced an increase, rather than a decrease, in CBV and recruited only neutrophils to the brain parenchyma (Blamire et al., 2000) . In peripheral tissues, IL1b and TNF-a have been reported to have similar effects, and it is surprising, therefore, that these cytokines have different effects within the CNS. Despite these differences, both cytokines result in a decrease in tissue water diffusion, although this is delayed in TNF-a-injected animals compared with IL-1b-injected animals. The implications of the current ®ndings are discussed below.
Effects of TNF-a on CBV
Our data demonstrate that there is a profound, acute reduction in striatal rCBV as a direct consequence of focal rrTNF-a injection. Few investigations of the effects of TNF-a on cerebral perfusion have been reported previously, and where data is available the results are somewhat contradictory. Megyeri and colleagues demonstrated vasoconstriction in pial arterioles following intracisternal injection of rhuTNF-a into newborn piglets (Megyeri et al., 1992) . In contrast, Brian and Faraci (1998) demonstrated dilation of pial arterioles following superfusion of the rat cortex with TNF-a. Both of these studies report the effects of TNF-a on the super®cial pial arterioles of the brain, rather than the intraparenchymal microvasculature. Similarly, large intracisternal injections of TNF-a have been shown to decrease whole brain CBF in rabbits (Tureen, 1995) , but to increase cortical blood¯ow in rats (Angstwurm et al., 1998) . Again, it is likely that in both studies the effects of TNF-a were exerted on the super®cial, rather than intraparenchymal vessels, and that the differences re¯ect either species or dose differences. In rat models of cerebral ischaemia, inhibition of endogenous TNF-a has been shown to improve microvascular perfusion (Dawson et al., 1996) and enhance cerebral blood¯ow during reperfusion (Lavine et al., 1998) . On this basis, it has been suggested that expression of TNF-a following focal cerebral ischaemia may contribute to impairment of microvascular perfusion, either as a consequence of recruited leukocytes obstructing cerebral vessels or via a direct vasoconstrictor effect of the cytokine itself (Dawson et al., 1996) . Our data demonstrate clearly that an intracerebral injection of rrTNF-a causes acute, temporary vasoconstriction of local parenchymal vessels that is independent of recruited leukocytes. Since the reduction in rCBV precedes monocyte recruitment, we hypothesized that this might occur via TNF-ainduced expression of endothelin peptides (ET-1 and ET-3), which are known vasoconstrictors. Many pathologies associated with increased cytokine production also exhibit elevated levels of circulating ET-1, and peripheral injection of TNF-a into rats signi®cantly increases plasma ET-1 concentrations within 15 min (Klemm et al., 1995) . Our data demonstrate that the vasoconstrictor effects of rrTNF-a within the brain parenchyma in vivo can be completely eliminated by prior administration of an ET receptor antagonist which blocks both ET A and ET B receptors (Clozel et al., 1993) . We suggest, therefore, that the observed effects of rrTNF-a on rCBV are mediated via the action of ET on its receptors. ET-1 production by both bovine and human cerebral endothelial cells in culture is increased by TNF-a (Durieu-Trautmann et al., 1993; Skopal et al., 1998) , and vascular smooth muscle cells have also been shown to secrete ET-1 in in¯ammatory lesions (Kedzierski and Yanagisawa, 2001) . It is likely, therefore, that the observed reduction in rCBV is caused by the action of TNF-a on the brain microvessel endothelial and smooth muscle cells to provoke the release of ET, which subsequently causes vasoconstriction, primarily through its action on the smooth muscle cell ET A receptors (Kedzierski and Yanagisawa, 2001) .
TNF-a binds to two transmembrane receptors of approximately 55 (p55, TNFR1) and 75 kDa (p75, TNFR2) (Aggarwal and Natarajan, 1996) . While the TNFR1 is ubiquitously expressed, the TNFR2 is predominantly expressed by haematopoietic and endothelial cells, and they are thought to activate distinct signalling pathways and mediate distinct cellular processes. The rrTNF-a used in these studies binds non-speci®cally to both TNF-a receptor subtypes, whilst rhuTNF-a will bind only to TNFR1 in rat brain (Lewis et al., 1991; Stefferl et al., 1996) . In contrast to rrTNF-a injection, intrastriatal injection of rhuTNF-a caused no reduction in rCBV. These data indicate that activation of the TNFR2, either alone or in combination with the TNFR1, is essential for the TNF-a-induced reduction in rCBV, and that activation of this pathway leads to ET release, probably via activation of the microvascular endothelial cells. These data may explain the discrepancies in TNF-a-mediated effects on cerebral perfusion reported previously, where rhuTNF-a was used in rodent studies before rrTNF-a became widely available.
In this study we have used a single bolus injection of TNFa into the striatum. Previously, we have demonstrated by ELISA that following a bolus injection of TNF-a, the level of immunoreactive TNF-a in the brain parenchyma has fallen to 50% of maximum after 4 h and is no longer quanti®able by 24 h (Anthony et al., 2001) . As a result, effects of TNF-a are likely to be short-lived under this experimental protocol in comparison to neurological conditions, in which TNF-a may be expressed chronically. Therefore, we used an adenovirusexpressing membrane-bound TNF-a cDNA to investigate the effects of prolonged TNF-a expression within the brain on rCBV. These experiments con®rmed the ®ndings of the single bolus study and demonstrated that longer durations of endogenous TNF-a expression cause a sustained reduction in rCBV. In experimental stroke models, it is well documented that a reduction of 80±90% in cerebral perfusion of short duration invariably results in energy failure and neuronal death (Tamura et al., 1981; Bolander et al., 1989) . However, much less severe reductions in cerebral perfusion, if prolonged, can also lead to neuronal death (Jacewicz et al., 1992) . Therefore, in neurological conditions where TNF-a expression is prolonged, this may cause a long-term perfusion de®cit that is detrimental to neuronal viability. Following the injection of adenovirus, it is clear that long-term expression of membrane-bound TNF-a can give rise to neuronal degeneration. However, at the present time it is unclear whether this is due to the reduction in rCBV, a direct action of TNF-a on the neurones, effects of molecules secreted from activated in¯ammatory cells, or a combination of all of these factors.
Both cerebral malaria (Kwiatkowski et al., 1990; Brown et al., 1999) and the Plasmodium berghei ANKA model of cerebral malaria (Neill and Hunt, 1995) are associated with high levels of cerebral TNF-a expression. Furthermore, a signi®cant increase in the expression of TNFR2, but not TNFR1, has been found on brain microvessels during cerebral malaria in susceptible mice, and mice de®cient in TNFR2 (but not those de®cient in TNFR1) are signi®cantly protected from experimental cerebral malaria (Lucas et al., 1997) . Thus, the effects of TNF-a on rCBV, mediated via the TNFR2 pathway and ET production, may be a contributing factor to neuronal dysfunction or degeneration in cerebral malaria, in which the causes of neuronal damage, and ultimately patient death, are still unknown.
Effects of TNF-a on B-CSF-B and BBB integrity
TNF-a is thought to play a role in BBB disruption associated with brain injury (Feuerstein et al., 1994; Yang et al., 1999) and bacterial meningitis (Sharief et al., 1992) , and in vitro has been shown to decrease the trans-endothelial resistance in cerebrovascular-derived endothelial cells (de Vries et al., 1996) . However, few studies have considered variations in BBB compromise between the different CNS compartments. In the current study, the early unilateral increase in B-CSF-B permeability (as distinct from BBB permeability) preceded leukocyte recruitment to the brain. This effect on the B-CSF-B may re¯ect direct actions of TNF-a on the vasculature, as studies with tracers (N.R.S and D.C.A., unpublished data) indicate that a bolus of¯uid (as injected in this study) will diffuse fairly rapidly out of the striatum and alongside the major cortical vessels, to reach the meninges within 1.5±2 h. Furthermore, the data indicate that the B-CSF-B breakdown is leukocyte-independent, since it preceded macrophage recruitment to the meninges and was no longer apparent at 72 h when recruited macrophages were numerous. Although monocytes can cross an intact BBB and B-CSF-B, breakdown of these barriers may facilitate presentation of chemokines and thus recruitment to the meninges.
In contrast, breakdown of the BBB within the brain parenchyma at 24 h was coincident with signi®cant macrophage recruitment to the parenchyma. This ®nding differs from our previous studies of BBB viability using HRP, in which only very minimal leakage of tracer, localized speci®cally to the larger parenchymal vessels, was observed 24 h after a single bolus intraparenchymal injection of TNF-a (Anthony et al., 1997) . In addition, the B-CSF-B breakdown observed at the early time points was visible by contrastenhanced MRI before it became detectable using HRP. The current data suggest, therefore, that contrast-enhanced MRI measurements offer a more sensitive method of detecting BBB/B-CSF-B permeability than the HRP method, probably owing to the considerably smaller molecular weight of the gadolinium-based agent (0.57 kDa) compared with HRP (40 kDa).
Pre-treatment with the non-speci®c ET receptor antagonist Ro 46-2005 had no effect on the changes in BBB and B-CSF-B permeability, suggesting that these events are not mediated by the TNF-a-induced ET pathway responsible for the rCBV reduction. However, the ET system is widespread in the brain, with ET A , ET B , ET-1 and ET-3 being expressed by vascular, neuronal and glial cells (Kedzierski and Yanagisawa, 2001) . Given that the Ro 46-2005 injection was administered intravenously, it is possible that it may not antagonize nonvascular effects of ET occurring deep within the brain parenchyma, such as the observed BBB breakdown and ADC reduction. Interestingly, there appeared to be a reduction in the degree of BBB permeability at 24 h following rhuTNF-a injection compared with the rrTNF-a-injected animals. These data suggest that both receptor pathways contribute to the processes underlying the BBB breakdown. Rosenberg and colleagues have previously demonstrated a dose-dependent parallel increase in capillary permeability and expression of proteolytic enzymes 24 h after intracerebral infusion of TNFa, which could be blocked by an inhibitor of matrix metalloproteinases (Rosenberg et al., 1995) . On this basis, they suggest that TNF-a may modulate delayed capillary permeability via the matrix metalloproteinase gelatinase B.
Effects of TNF-a on tissue water diffusion
The areas of reduced tissue water ADC observed at 24 h corresponded to the regions of BBB breakdown, and indicate a relatively widespread effect of the focal cytokine injection. Again, this is likely to result from spread of the injected bolus to neighbouring cortical regions. Reduced tissue water diffusion has been extensively documented in acute brain ischaemia (Hoehn-Berlage, 1995) , although the exact mechanisms responsible for these changes remain unclear. In ischaemia, the temporal evolution of reduced diffusion appears to follow the loss of high-energy metabolites (van der Toorn et al., 1996) and is thought to re¯ect compromise of tissue energy metabolism. Observations of a transient reduction in ADC during spreading depression (Latour et al., 1994) indicate that changes in tissue water diffusion are linked to disruption of tissue energy homeostasis, rather than ischaemia per se. This hypothesis is supported by our previous ®nding that IL-1b causes a reduction in ADC that is accompanied by an increase in rCBV and no indicators of ischaemia (Blamire et al., 2000) . In the current study, rCBV was found to be normal within the areas of reduced ADC at 24 h, again suggesting that ischaemia is unlikely to be the cause of these changes.
As with the BBB permeability changes, pre-treatment with the non-speci®c ET receptor antagonist Ro 46-2005 had no effect on the observed ADC reduction, although as discussed above this does not necessarily preclude the ET system from playing a role in these changes. However, it does indicate that the reduction in ADC is independent of the acute reduction in rCBV. In animals injected intrastriatally with rhuTNF-a, there appeared to be a dose-dependent effect on tissue ADC. This ®nding suggests that, as for the BBB permeability changes, the pathways induced by both TNF-a receptors may be involved in the processes underlying the ADC changes. Moreover, the reduction in ADC may be a consequence of BBB breakdown, which spatially corresponded closely to the region of decreased ADC. Alternatively, the ADC changes may be induced by direct effects of the cytokine on cellular metabolism and function. It has been shown that TNF-a is not directly toxic to neurones (Piani et al., 1992; Barone et al., 1997) . However, recent studies have shown that TNF-a markedly inhibits glutamate uptake in both human and rat astrocytes in culture (Fine et al., 1996; Ye and Sontheimer, 1996; Hu et al., 2000) . Thus, glutamate-induced toxicity and resultant energetic compromise of neurones may contribute to the observed reduction in tissue water diffusion at 24 h. It has also been suggested that TNF-a may impair the ability of astrocytes to provide adequate energy substrates to neurones for oxidation (Yu et al., 1995) , which also could result in neuronal dysfunction.
In summary, these studies demonstrate that a single bolus injection of TNF-a into the brain parenchyma gives rise to an acute reduction in rCBV, followed by breakdown of the BBBs and a reduction in tissue water diffusion. Furthermore, chronic expression of TNF-a in the brain leads to a prolonged CBV de®cit. These observations identify detrimental consequences of TNF-a in the brain which may contribute to neuronal dysfunction and degeneration in CNS injury and disease. Our data suggest that both endothelin receptors and the TNFR2 pathway are potential targets for therapeutic intervention in neuropathologies, such as multiple sclerosis, cerebral malaria and HIV encephalitis that are associated with high cerebral TNF-a expression.
